Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.766
+0.346 (14.30%)
At close: Jan 22, 2026, 4:00 PM EST
2.690
-0.076 (-2.75%)
After-hours: Jan 22, 2026, 6:05 PM EST
Xenetic Biosciences Revenue
Xenetic Biosciences had revenue of $1.03M in the quarter ending September 30, 2025, with 67.19% growth. This brings the company's revenue in the last twelve months to $2.86M, up 13.30% year-over-year. In the year 2024, Xenetic Biosciences had annual revenue of $2.50M, down -1.56%.
Revenue (ttm)
$2.86M
Revenue Growth
+13.30%
P/S Ratio
1.48
Revenue / Employee
$1,429,468
Employees
2
Market Cap
6.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.50M | -39.70K | -1.56% |
| Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
| Dec 31, 2022 | 1.71M | 546.23K | 47.06% |
| Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
| Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
| Dec 31, 2019 | 17.07K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 7.59M | 4.59M | 152.83% |
| Dec 31, 2016 | 3.00M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 1.00M | - | - |
| Sep 30, 2013 | - | - | - |
| Dec 31, 2012 | 293.60K | - | - |
| Aug 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionXBIO News
- 6 weeks ago - Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire
- 6 months ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Accesswire
- 6 months ago - Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer - Accesswire